Sovereign AI for Pharma and Life Sciences

Sovereign AI for pharma keeps formulations and batch records inside the validated environment and traces every answer to its source, so quality and regulatory teams can defend it.

Sovereign AI here. Sovereign AI keeps formulations, trial data and batch records inside the validated environment, so regulated decisions rest on traceable, in-house evidence rather than a black box.

Sector reality

The challenge

A quality lead cannot release a batch until deviations, specifications and results line up, and the evidence lives across the lab, the shop floor and the quality system. In a GMP world, an answer you cannot trace is an answer you cannot use, and a leak of proprietary formulation is existential.

01
Proprietary IP must stay in.

Molecule structures, trial data and formulations are the core asset, and public AI risks leakage and absorption into a model.

02
Data integrity under non-deterministic AI.

GxP records must meet ALCOA principles, so AI needs full audit trails, versioning and reproducibility.

03
Regulated decisions need traceability.

An unexplained answer from a black box cannot support a batch release, a submission or an audit.

The picture

Inside your tenant, and no further

Diagram: your pharma and life sciences systems on the left, the KLapper Private AI Companion powered by Cerveau inside your own Microsoft Azure tenant in the middle with your permissions mirrored, and one cited answer on the right. Nothing crosses the tenant boundary.
How it fits together. Your pharma and life sciences systems on the left. KLapper and Cerveau inside your own Microsoft Azure tenant in the middle, with your permissions mirrored. One cited answer on the right. Nothing crosses the boundary: your data is never sent to a public model and is never used to train one.
Regulation

Why sovereignty is non-negotiable here

FDA 21 CFR Part 11, EU GMP Annex 11, GxP and ALCOA data-integrity principles, the FDA's 2025 draft guidance on AI in regulatory decisions and the EMA reflection paper on AI in the medicines lifecycle all demand validated, traceable systems.

What applies
21 CFR Part 11
EU GMP Annex 11
GxP and ALCOA
FDA 2025 draft guidance
EMA reflection paper
Evidence

Industry signal, industry voice

Industry signal

McKinsey estimates generative AI could create tens of billions of dollars in annual value for pharma and medical products, while the FDA's January 2025 draft guidance sets a risk-based credibility framework for AI in regulated decisions (McKinsey; FDA, 2025).

Industry voice

Announcing its 2025 draft guidance, FDA Commissioner Robert Califf said the agency is “committed to supporting innovative approaches... by providing an agile, risk-based framework that promotes innovation and ensures the agency's robust scientific and regulatory standards are met” (FDA, 2025).

The pattern

How KLapper helps

01
Science stays in the validated environment.

KLapper keeps formulations and batch records inside the plant and grounds answers in LIMS, MES, QMS and ERP.

02
Every answer is traced to source.

Cerveau turns the black box into a glass box that quality and regulatory teams can defend.

03
Audit-ready by design.

Answers are cited and human-reviewed, supporting Part 11 and ALCOA expectations.

Outcomes

The value

01
Faster, defensible quality decisions.

Batch and deviation questions answered in minutes, with traceable evidence.

02
IP protection.

Formulations and trial data never leave the validated environment.

03
Regulator-ready AI.

Traceable, reviewed answers fit GxP and data-integrity duties.

Systems it reads
LIMSMESQMSERPELNRIMSand more
FAQ

Sovereign AI, answered

01What is Sovereign AI?

Sovereign AI is the principle that an institution should own, protect and control its own intelligence, running AI inside an environment it controls so its data and knowledge never leave and are never used to train public models.

02Can AI meet GxP and data integrity?

Yes, when it runs in your validated environment, cites its evidence, keeps a full audit trail, and keeps a human in the loop, in line with 21 CFR Part 11 and ALCOA.